Lydia J. Davis
Research Subjects
Lydia J. Davis has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Jimmy Orjala
Department of Pharmaceutical Sciences, Retzky College of Pharmacy, University of Illinois, Chicago, Chicago, IL 60612, USA
3 shared publications - Joanna E. Burdette
Department of Pharmaceutical Sciences, University of Illinois Chicago, Chicago, USA
3 shared publications Aleksej Krunic
Department of Pharmaceutical Sciences
2 shared publications- Manead Khin
Department of Pharmaceutical Sciences, University of Illinois at Chicago, Chicago, Illinois, USA
2 shared publications Aleksej Krunić
Department of Pharmaceutical Sciences, College of Pharmacy
1 shared publication- Alessandra S. Eustaquio
Department of Pharmaceutical Sciences, Retzky College of Pharmacy, University of Illinois Chicago
1 shared publication
Latest Publications
- Open Access
- 21 January 2026
- Published by American Chemical Society (ACS) in Journal of Natural Products
- Vol. 89 (2) , 573-583
Discovery of Suomilide and Cyanopeptolin Analogues by 15 N Stable Isotope Labeling and Genome Mining of Cyanobacteria
Cyanobacteria have been a promising source for natural product drug discovery for decades using mainly activity-guided approaches. More recently, genome mining and bioinformatics-guided approaches have become increasingly utilized in bacterial drug discovery and have proven to be successful in revealing novel metabolites predicted by biosynthetic gene clusters. However, detection and identification of these predicted metabolites can be difficult. Connecting nitrogen-containing natural products with the corresponding gene clusters encoding them in cyanobacteria can be aided by cyanobacteria's ability to incorporate inorganic nitrogen into their secondary metabolites. Feeding cyanobacteria with 15N-labeled and 14N nitrate and comparing the resulting metabolic profiles via mass spectrometry allows for the identification of nitrogen-containing metabolites, which can then be connected to biosynthetic gene clusters. Investigation of Nostoc sp. UIC 10890 using this workflow identified 28 total gene clusters and five groups of masses incorporating 15N-labeled nitrogen. Two of these groups contained new compounds, and the structures were elucidated by NMR and MS/MS. Three new compounds suomilide F, cyanopeptolin UIC949, and cyanopeptolin UIC999 were shown to have inhibitory activity against different serine proteases.
- 21 January 2026
- Published by American Chemical Society (ACS) in Journal of Natural Products
- Vol. 89 (2) , 573-583
Open AccessDiscovery of Suomilide and Cyanopeptolin Analogues by 15 N Stable Isotope Labeling and Genome Mining of Cyanobacteria
Cyanobacteria have been a promising source for natural product drug discovery for decades using mainly activity-guided approaches. More recently, genome mining and bioinformatics-guided approaches have become increasingly utilized in bacterial drug discovery and have proven to be successful in revealing novel metabolites predicted by biosynthetic gene clusters. However, detection and identification of these predicted metabolites can be difficult. Connecting nitrogen-containing natural products with the corresponding gene clusters encoding them in cyanobacteria can be aided by cyanobacteria's ability to incorporate inorganic nitrogen into their secondary metabolites. Feeding cyanobacteria with 15N-labeled and 14N nitrate and comparing the resulting metabolic profiles via mass spectrometry allows for the identification of nitrogen-containing metabolites, which can then be connected to biosynthetic gene clusters. Investigation of Nostoc sp. UIC 10890 using this workflow identified 28 total gene clusters and five groups of masses incorporating 15N-labeled nitrogen. Two of these groups contained new compounds, and the structures were elucidated by NMR and MS/MS. Three new compounds suomilide F, cyanopeptolin UIC949, and cyanopeptolin UIC999 were shown to have inhibitory activity against different serine proteases.
- 20 February 2025
- Published by American Chemical Society (ACS) in Journal of Natural Products
- Vol. 88 (3) , 732-746
Menominin A and B: Cytotoxic Cyclodepsipeptides from the Freshwater Sponge-Associated Cyanobacterium Nostoc sp. UIC 10607
Menominin A (1) and B (2), two cyclodepsipeptides containing a 3,8-dihydroxy-2-methyltetradecanoic acid residue, were isolated from the freshwater sponge-associated cyanobacterium, Nostoc sp. UIC 10607, using bioactivity-guided and spectroscopic approaches. The planar structures of 1 and 2 were established using HRESIMS and one- and two-dimensional NMR experiments. Comparative genomic analysis revealed unique differences in the putative menominin biosynthetic gene cluster compared to that of the closely related cyanobacterial cyclic lipodepsipeptide, hapalosin, assisting in structure elucidation and highlighting the structural diversity of this class of compounds. Configuration assignments were determined using a combination of J-based configuration analysis, chiral HPLC, modified Mosher's ester analysis, and DFT calculations. Menominin A and B demonstrate antiproliferative bioactivity against the high-grade serous ovarian cancer cell line OVCAR3 (IC50 = 3.1 (1) and 2.4 μM (2)). Menominin A and B are the first reported secondary metabolites from a freshwater sponge-associated cyanobacterium, underscoring the potential of freshwater sponges as a microbial culture source in natural product discovery.
- 20 February 2025
- Published by American Chemical Society (ACS) in Journal of Natural Products
- Vol. 88 (3) , 732-746
Menominin A and B: Cytotoxic Cyclodepsipeptides from the Freshwater Sponge-Associated Cyanobacterium Nostoc sp. UIC 10607
Menominin A (1) and B (2), two cyclodepsipeptides containing a 3,8-dihydroxy-2-methyltetradecanoic acid residue, were isolated from the freshwater sponge-associated cyanobacterium, Nostoc sp. UIC 10607, using bioactivity-guided and spectroscopic approaches. The planar structures of 1 and 2 were established using HRESIMS and one- and two-dimensional NMR experiments. Comparative genomic analysis revealed unique differences in the putative menominin biosynthetic gene cluster compared to that of the closely related cyanobacterial cyclic lipodepsipeptide, hapalosin, assisting in structure elucidation and highlighting the structural diversity of this class of compounds. Configuration assignments were determined using a combination of J-based configuration analysis, chiral HPLC, modified Mosher's ester analysis, and DFT calculations. Menominin A and B demonstrate antiproliferative bioactivity against the high-grade serous ovarian cancer cell line OVCAR3 (IC50 = 3.1 (1) and 2.4 μM (2)). Menominin A and B are the first reported secondary metabolites from a freshwater sponge-associated cyanobacterium, underscoring the potential of freshwater sponges as a microbial culture source in natural product discovery.
- 30 July 2024
- Published by Elsevier in Molecular Pharmacology
- Vol. 106 (3) , 145-154
Aulosirazole Stimulates FOXO3a Nuclear Translocation to Regulate Apoptosis and Cell-Cycle Progression in High-Grade Serous Ovarian Cancer (HGSOC) Cells
Ovarian cancer, the fifth leading cause of cancer-related mortality in women, is the most lethal gynecological malignancy globally. Within various ovarian cancer subtypes, high-grade serous ovarian cancer (HGSOC) is the most prevalent and there is frequent emergence of chemoresistance. Aulosirazole, an isothiazolonaphthoquinone alkaloid, isolated from the cyanobacterium Nostoc sp. UIC 10771, demonstrated cytotoxic activity against OVCAR3 cells (IC50 = 301 {plus minus} 80 nM). Using immunocytochemistry, OVCAR3 cells treated with aulosirazole demonstrated increased concentrations of pAKT and pJNK with subsequent accumulation of FOXO3a in the nucleus. The combination of aulosirazole with AKT inhibitors resulted in the most nuclear accumulation of FOXO3a Aulosirazole induced apoptosis based on cleavage of PARP, Annexin V staining, and induction of caspase 3/7 activity in OVCAR3, OVCAR5 and OVCAR8. The expression of downstream targets of FOXO3a, including BCL2 and PUMA, significantly increased following aulosirazole treatment. Aulosirazole upregulated the FOXO3a target, p21, and increased cell cycle arrest in the G0/G1 phase. The downregulation of FOXO3a by shRNA reduced the cytotoxicity after aulosirazole treatment by threefold IC50 (949 {plus minus} 16 nM) and eliminated its ability to regulate downstream targets of FOXO3a. These findings underscore FOXO3a as a critical mediator of aulosirazole-induced cytotoxicity. Additionally, aulosirazole was able to decrease migration and invasion while increasing cell death in3D tumor spheroids. However, in vivo OVCAR8 tumor burden was not significantly reducedby aulosirazole using an intraperitoneal tumor model. Given the mechanism of action of aulosirazole, this class of alkaloids represents promising lead compounds to develop treatments against FOXO3a-downregulated cancers. Significance Statement Aulosirazole, an isothiazolonaphthoquinone alkaloid, exhibits potent cytotoxic effects against HGSOC by promoting FOXO3a nuclear accumulation and modulating downstream targets. These findings highlight the potential of aulosirazole as a promising therapeutic intervention for cancers characterized by FOXO3a downregulation.
- 30 July 2024
- Published by Elsevier in Molecular Pharmacology
- Vol. 106 (3) , 145-154
Aulosirazole Stimulates FOXO3a Nuclear Translocation to Regulate Apoptosis and Cell-Cycle Progression in High-Grade Serous Ovarian Cancer (HGSOC) Cells
Ovarian cancer, the fifth leading cause of cancer-related mortality in women, is the most lethal gynecological malignancy globally. Within various ovarian cancer subtypes, high-grade serous ovarian cancer (HGSOC) is the most prevalent and there is frequent emergence of chemoresistance. Aulosirazole, an isothiazolonaphthoquinone alkaloid, isolated from the cyanobacterium Nostoc sp. UIC 10771, demonstrated cytotoxic activity against OVCAR3 cells (IC50 = 301 {plus minus} 80 nM). Using immunocytochemistry, OVCAR3 cells treated with aulosirazole demonstrated increased concentrations of pAKT and pJNK with subsequent accumulation of FOXO3a in the nucleus. The combination of aulosirazole with AKT inhibitors resulted in the most nuclear accumulation of FOXO3a Aulosirazole induced apoptosis based on cleavage of PARP, Annexin V staining, and induction of caspase 3/7 activity in OVCAR3, OVCAR5 and OVCAR8. The expression of downstream targets of FOXO3a, including BCL2 and PUMA, significantly increased following aulosirazole treatment. Aulosirazole upregulated the FOXO3a target, p21, and increased cell cycle arrest in the G0/G1 phase. The downregulation of FOXO3a by shRNA reduced the cytotoxicity after aulosirazole treatment by threefold IC50 (949 {plus minus} 16 nM) and eliminated its ability to regulate downstream targets of FOXO3a. These findings underscore FOXO3a as a critical mediator of aulosirazole-induced cytotoxicity. Additionally, aulosirazole was able to decrease migration and invasion while increasing cell death in3D tumor spheroids. However, in vivo OVCAR8 tumor burden was not significantly reducedby aulosirazole using an intraperitoneal tumor model. Given the mechanism of action of aulosirazole, this class of alkaloids represents promising lead compounds to develop treatments against FOXO3a-downregulated cancers. Significance Statement Aulosirazole, an isothiazolonaphthoquinone alkaloid, exhibits potent cytotoxic effects against HGSOC by promoting FOXO3a nuclear accumulation and modulating downstream targets. These findings highlight the potential of aulosirazole as a promising therapeutic intervention for cancers characterized by FOXO3a downregulation.
- 31 January 2022
- Published by American Chemical Society (ACS) in Journal of Natural Products
- Vol. 85 (3) , 540-546
Aulosirazoles B and C from the Cyanobacterium Nostoc sp. UIC 10771: Analogues of an Isothiazolonaphthoquinone Scaffold that Activate Nuclear Transcription Factor FOXO3a in Ovarian Cancer Cells
The known solid-tumor-selective cytotoxin aulosirazole (1) was identified from bioactive extracts from the culture medium of the cyanobacterium Nostoc sp. UIC 10771. Here, we demonstrate that 1 induces the nuclear accumulation of FOXO3a in OVCAR3 using both Western blot analysis and immunofluorescence confocal microscopy. We also report the discovery of two additional analogues, aulosirazoles B (2) and C (3). Structures for compounds 2 and 3 were determined using HR-ESI-LC-MS/MS and 1D and 2D NMR experiments. Aulosirazoles B (2) and C (3) represent the first natural analogues of the FOXO-activating compound aulosirazole (1) and are the second and third isothiazole-containing metabolites reported from this phylum.
- 31 January 2022
- Published by American Chemical Society (ACS) in Journal of Natural Products
- Vol. 85 (3) , 540-546
Aulosirazoles B and C from the Cyanobacterium Nostoc sp. UIC 10771: Analogues of an Isothiazolonaphthoquinone Scaffold that Activate Nuclear Transcription Factor FOXO3a in Ovarian Cancer Cells
The known solid-tumor-selective cytotoxin aulosirazole (1) was identified from bioactive extracts from the culture medium of the cyanobacterium Nostoc sp. UIC 10771. Here, we demonstrate that 1 induces the nuclear accumulation of FOXO3a in OVCAR3 using both Western blot analysis and immunofluorescence confocal microscopy. We also report the discovery of two additional analogues, aulosirazoles B (2) and C (3). Structures for compounds 2 and 3 were determined using HR-ESI-LC-MS/MS and 1D and 2D NMR experiments. Aulosirazoles B (2) and C (3) represent the first natural analogues of the FOXO-activating compound aulosirazole (1) and are the second and third isothiazole-containing metabolites reported from this phylum.